John Robinson recruits a small band of Array vets to kickstart discovery at Cogent; Syntimmune co-founder takes charge at Arch Oncology
Biotech is a small world — and all the more so in a tight-knit community like Boulder, CO.
A serendipitous reunion with Andrew Robbins, a former colleague at Array, was what sparked John Robinson’s jump to his new gig as CSO of Cogent Biosciences.
He had started following the company, a reincarnation of the troubled cell therapy biotech Unum Therapeutics, after it tapped Robbins as CEO. The two had worked on multiple projects together at Array — as Robinson shepherded to the clinic what eventually became Mektovi, Tukysa, Vitrakvi, Retevmo and Koselugo — but parted ways after Pfizer bought it for $11.4 billion. Robinson stayed on at the pharma giant, most recently getting elevated to VP of medicinal chemistry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.